Merck KGAA, the diversified Germany-based multinational company, unveiled what it called a “more balanced” R&D pipeline for its pharmaceuticals division Merck Serono SA during its 2012 annual results analysts’ call March 7.
There is now a greater focus on Phase I/II compounds, and Merck will try to share the risks of development with other companies, Merck executives said. Furthermore, there will be...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?